Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

13 Sept 2019

Abstract excerpt

OBJECTIVES: Hepatocellular carcinoma (HCC) is one of the most frequent malignancies and a major leading cause of cancer-related deaths worldwide. Several therapeutic options like sorafenib and regorafenib provide only modest survival benefit to patients with HCC. This study aims to identify novel druggable candidate genes for patients with HCC. DESIGN: A non-biased CRISPR (clustered regularly interspaced short...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31519701
DOI: 10.1136/gutjnl-2019-318506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinomaPMID 31519701Read ↗

Genome-wide functional CRISPR screen reveals CDK7 as a targetable therapeutic vulnerability for head and neck cancerSemantic proximity Read ↗

Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitorsSemantic proximity Read ↗

SR-4835, a CDK12 inhibitor, enhances the antitumor efficacy of sunitinib in human renal cell carcinoma through suppression of the ATR-associated DNA damage response pathway: an in vitro and in vivo studySemantic proximity Read ↗

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSemantic proximity Read ↗

Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibitionSemantic proximity Read ↗

Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitorsSemantic proximity Read ↗

NOTCH1 regulates the DNA damage response and sorafenib resistance by activating ATM in hepatocellular carcinomaSemantic proximity Read ↗

CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinomaSemantic proximity Read ↗

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCCSemantic proximity Read ↗

CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar CarcinomaSemantic proximity Read ↗

CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinomaSemantic proximity Read ↗

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.